Credit Suisse Previews Biogen, Says 'Consensus Tecfidera Downgrades = Pipeline Buying Opportunity'

By: via Benzinga
Credit Suisse on Thursday previewed Biogen Idec Inc (NASDAQ: BIIB) ahead of its fourth-quarter results. Biogen is rated as Outperform ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.